Individual with ten fold higher risk to develop pancreatic cancer.

Hereditary Pancreatitis

Hereditary Pancreatic Cancer

Gastrocentrum Karolinska University Hospital

Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.

Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer

MRI accuracy in detection precancerous pancreatic lesions.

Matthias Löhr

Professor

Karolinska University Hospital

The patients at this arm were allowed to take food through mouth

Closure of POPF After Pancreaticoduodenectomy

The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth

Jejunostomy tube feeding

National Taiwan University Hospital

Route of Nutritional Support for Pancreatic Fistula

Nutrition Through Oral Intake Versus Feeding Jejunostomy in the Conservative Treatment of Pancreatic Fistula After Pancreaticoduodenectomy: a Prospective Multicenter Randomized Clinical Trial

Adults diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

Adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer.
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

Adults age 35-99 with Peutz-Jeghers syndrome.
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

Adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

10 adults, diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

New Onset Diabetes

10 adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

Familial Pancreatic Cancer

10 adults age 35-99 with Peutz-Jeghers syndrome.
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

Peutz-Jeghers Syndrome

10 adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.

Clinical Symptoms of Pancreatic Cancer, Normal CT

Total

Gender

Region of Enrollment

Subjects will receive the secretin test dose just prior to the CT scan. Definitions: Evidence of Pancreatic Tumor (low-attenuation mass), Secondary Findings of Pancreatic Tumor such as dilated pancreatic duct or liver masses suggestive of liver metastases.

Adults, diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

Adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer
All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study.

Number of Subjects With Evidence of Pancreatic Tumor or Any Secondary Findings of Pancreatic Tumor as Shown by CT.

Adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.

secretin/atrofia

Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.

Route of Nutritional Support for Pancreatic Fistula

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo